3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
2573
Uterine Cervical Neoplasms
1693
Endometrial Neoplasms
1012
Fallopian Tube Neoplasms
730
Carcinoma, Ovarian Epithelial
681
Breast Neoplasms
676
Neoplasms
436
Carcinoma, Non-Small-Cell Lung
379
Colorectal Neoplasms
372
Stomach Neoplasms
302
Pancreatic Neoplasms
302
Uterine Cervical Dysplasia
273
Prostatic Neoplasms
262
Lung Neoplasms
250
Melanoma
247
Neoplasm Metastasis
216
Peritoneal Neoplasms
197
Carcinoma, Renal Cell
193
Sarcoma
190
Head and Neck Neoplasms
189
Urinary Bladder Neoplasms
187
Esophageal Neoplasms
187
Recurrence
185
Triple Negative Breast Neoplasms
181
Uterine Neoplasms
176
Vulvar Neoplasms
173
Squamous Cell Carcinoma of Head and Neck
168
Colonic Neoplasms
162
Papillomavirus Infections
153
Small Cell Lung Carcinoma
128
Interventions
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Paclitaxel
1
Gemcitabine
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
×
Gynecologic
×
Clear all
NCT04274426
2026-05-13
MIROVA
AGO Research GmbH
Phase 2
Active not recruiting
136 enrolled